We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
126
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$3.61M 0.14%
+60,390
New +$3.73M
RMD icon
127
ResMed
RMD
$30.6B
$3.42M 0.13%
17,831
– –
LGND icon
128
Ligand Pharmaceuticals
LGND
$5.76B
$3.42M 0.13%
49,036
– –
EPZM
129
DELISTED
Epizyme, Inc
EPZM
$3.34M 0.13%
207,752
– –
KRTX
130
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.33M 0.13%
+29,873
New +$2.6M
YMAB
131
DELISTED
Y-mAbs Therapeutics
YMAB
$3.31M 0.13%
76,548
– –
ALKS icon
132
Alkermes
ALKS
$8.22B
$3.3M 0.13%
169,930
– –
ACHC icon
133
Acadia Healthcare
ACHC
$2.76B
$3.3M 0.13%
131,200
– –
CRL icon
134
Charles River Laboratories
CRL
$11.2B
$3.22M 0.12%
18,467
– –
ARWR icon
135
Arrowhead Research
ARWR
$11.9B
$3.2M 0.12%
74,186
– –
CRBP icon
136
Corbus Pharmaceuticals
CRBP
$166M
$3.18M 0.12%
+12,624
New +$2.55M
ZLAB icon
137
Zai Lab
ZLAB
$2.06B
$3.08M 0.12%
37,523
– –
GWPH
138
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.07M 0.12%
25,051
-25,050
-50% -$2.84M
QTNT
139
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.05M 0.12%
10,298
+3,797
+58% +$1.09M
HR
140
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.05M 0.12%
104,024
– –
DXCM icon
141
DexCom
DXCM
$31.5B
$2.94M 0.11%
+29,004
New +$2.59M
QURE icon
142
uniQure
QURE
$3.03B
$2.84M 0.11%
63,039
+19,190
+44% +$1.13M
PRGO icon
143
Perrigo
PRGO
$1.4B
$2.83M 0.11%
51,224
+40,406
+374% +$2.13M
ALGN icon
144
Align Technology
ALGN
$12.1B
$2.76M 0.1%
10,041
– –
OVID icon
145
Ovid Therapeutics
OVID
$414M
$2.75M 0.1%
372,733
– –
INSM icon
146
Insmed
INSM
$21.4B
$2.71M 0.1%
98,387
– –
ANAB icon
147
AnaptysBio
ANAB
$1.58B
$2.64M 0.1%
118,261
– –
PHG icon
148
Philips
PHG
$25.7B
$2.61M 0.1%
68,800
-1,396
-2% -$48.6K
AXSM icon
149
Axsome Therapeutics
AXSM
$11.2B
$2.6M 0.1%
31,591
– –
BHVN
150
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.51M 0.1%
34,277
-10,887
-24% -$579K
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.